| INTRODUCTION
Measurement of glycated hemoglobin (HbA1c), a glycation product (1-deoxyfructosyl) of the N-terminal valine in the β globin chain of hemoglobin (Hb) A 0 , provides the most important medium-to long-term marker of time-averaged glycemic status. Its relationship with likely clinical outcome in diabetes mellitus has been convincingly demonstrated for both type I and type II patients in major clinical trials. 1, 2 For over two decades, measurement of HbA1c has been widely used as a means to retrospectively evaluate long-term glycemic control in diabetic patients. More recently, the International Expert Committee published a report recommending that type 2 diabetes be diagnosed when HbA1c ≥6.5% (48 mmol/mol). 3 An extension of the role of this Hb fraction, from monitoring to the screening and diagnosis of diabetes, leads to the possibility of even greater demand for this analysis. improvements have allowed analysis times to be reduced.
We have evaluated the analytical performance of the ADAMS ™ A1c HA-8180T (ARKRAY, Inc., Kyoto, Japan) analyzer, assessing the quality of the measurement of HbA1c.
| MATERIALS AND METHODS

| ADAMS ™ A1c HA-8180T
This is a fully automated HPLC analyzer. The system has been designed to provide the maximum amount of information in the shortest possible time. It combines the sensitivity and specificity of HPLC with automation software.
Working with the β-thalassemia screening mode, the analysis time is 3.5 min. The system quantitates HbF, HbA 2 , HbA 0 , and flags abnormal peaks; and common variants HbS and HbC can be detected as separate peaks on the chromatogram (Figure 1 ).
The analyzer is equipped with an autosampler, barcode reader and cap piercing. Continuous measurements can be made on up to 100 samples with bidirectional communication with a laboratory information system. The measurement principle is based on reversed phase cation exchange chromatography using a stepwise elution system driven by a single pump; the column is kept at 39°C with thermostatic control.
The system can handle both whole bloods and manually diluted samples. Four microlitre of whole blood are automatically sampled, hemolyzed and injected into the column. Hb molecules elute with inorganic phosphate buffers (80A, 80B, and 80CT) from low to high polarity. Upon elution, sample components pass through the spectrophotometric detector where fractions are monitored with dual wavelength detection (420 and 500 nm).
The total area of all peaks is a critical factor in the quality of the results. When the total area of the chromatogram is less than 15000, the anemia measurement mode can be selected and the anemia rack is used: the analyzer automatically changes the dilution ratio (standard, 1:100; anemia, 1:50) to provide accurate results even if in the presence of severe anemia.
Two-point calibration is employed; raw data are integrated and a chromatogram report is generated. Quality-control results can be stored; mean and standard deviation are automatically calculated for each HbA2 level; and Levey-Jennings graphs are also plotted. 
| Samples and controls
| Analytical performance evaluation
To conduct the evaluation, we followed the recommendations of the manufacturer and guidelines of the Clinical Laboratory Standards Institute (CLSI). 4 Carry over and within-run precision were evaluated in accordance with the CLSI EP10-A3 guideline. Specifically, carry over was assessed by analyzing a sample with high values three times (H1, H2, and H3)
followed immediately by a sample with low levels (L1, L2, and L3); the percentage of carry over was calculated using the following formula (L1-L3)/(H3-L2)*100.
Trueness was evaluated following the manufacturer's guidelines, analyzing two commercial controls per run for over 20 days. Mean value and standard deviation were calculated; bias was recorded as an absolute value and as a percentage.
For within-run precision, three samples one from a healthy subject,
another from a patient with poorly controlled diabetes and another at the diagnostic threshold of 7.0% (53 mmol/mol) were analyzed 10 times each within the same run. The mean and coefficient of variation (CV) were calculated.
Within-laboratory precision was tested by analyzing two commercial controls with different levels of HbA1c; in accordance with CLSI EP5-A2 guidelines both controls were analyzed twice over a 20-day period.
Linearity was investigated by sample mixing to evaluate the response to increasing concentrations of the measurand (CLSI guideline EP6). Specifically, the linearity of the method was evaluated by The effect of a wide range of concentrations of total Hb was evaluated; the experiment was performed twice with samples from a healthy subject and another from a patient with poorly controlled diabetes.
Potential interference from the labile fraction (LA1c) was also investigated; pooled blood from non-diabetic adults (HbA1c 31 mmol/ mol, 5.0%) was poured into six tubes and increasing volumes of glucose solution was added to these test samples; final glucose concentrations ranged from 11.1 to 55.5 mmol/L. The samples were incubated for 2 h at 37º C, and then analyzed. 
| Numerical analysis
We used MedCalc (version 16.2; MedCalc Software, Ostend, Belgium;
https://www.medcalc.org; 2016) for the analysis.
| RESULTS
Using samples with concentrations of 30 and 104 mmol/mol (4.9 and 11.7%), no carry over was detected. That is, there was no increase in the value obtained with the low concentration sample. and 102 mmol/mol (11.5%), and the CV was 0.4% for a concentration of 53 mmol/mol (7.0%), that is, at the diagnostic threshold. Withinlaboratory imprecision (commercial controls) is summarized in Table 1 .
Linearity was confirmed at the concentration range of 38-113 mmol/mol (5.6-12.5%):
Slope 95% CI 0.824-1.043; intercept 95% CI −0.31-1.54 ( Figure 2 ).
The measured values correlated with theoretical ones; the mean proportion recovered was 98.5%.
Results were reliable across a wide range of Hb. In particular, an 
| DISCUSSION
There is a high demand for HbA1c testing in the clinical laboratory and therefore efficiency is required. Efforts of manufacturers have contributed to improvements in the analyzers, creating faster systems. On the other hand, therapeutic strategies rely on reproducible and unbiased methods. These analytical and clinical requirements become even more important now that it has been accepted that HbA1c level can be used for the diagnosis of diabetes. In this context, guidelines and recommendations were published suggesting an intra-laboratory CV <2.0%.
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The analyzer achieved this stringent target in the study, with between-day CVs of 0-0.36%, and total CVs of 0.48-0.93%; the evaluation revealed excellent reproducibility, far beyond the stringent requirements.
Actually, desirable specifications have been published for total error, imprecision and bias, derived from intra-and inter-individual
T A B L E 1 Imprecision study HbA1c. Total precision was investigated using CLSI EP5-A2 guideline: over a 20 working days period, two commercial controls with different concentrations are run in duplicate twice a day in analytical runs of at least 10 samples and CV g , respectively). 6 Derived from 0.9% (imprecision) and 1.5%
(bias), the total allowable error is set at 3.0%, applying the following equation:
Total analytical error (TAE) includes bias and imprecision (CV a ):
The total error in the present evaluation was found to be 1.74%
(mean bias of 0.365% and mean CV a of 0.705%), and this meets the quality standards.
Quality requirements can also be calculated based on likelihood ratios 7 or the reference change value (RCV), which combines the two sources of variation, and is defined as the critical difference between two consecutive HbA1c measurements, representing a significant change in health status at a probability of 95%:
Considering a difference of 0.5% to be statistically significant at an HbA1c concentration of 7.0% (5.0 mmol/mol at 53 mmol/ mol), the goal for HbA1c measurement, an appropriate goal in terms of CV a can be calculated. Assuming that the mean CV w is 1.9% 6 , then the maximum allowable CV a is 1.9%; 8 in our evaluation, the total CV was 0.93% at a normal HbA1c level, and this satisfies the requirements. In the same way, we have shown the absence of interference from AcHb in the HbA1c measurement. This modified Hb is found in pregnant women, alcoholic patients and even patients being treated with aspirin; it is not an analytical issue since there is no variation in HbA1c quantitation in the presence of high concentrations of AcHb.
The results produced by the system under review were found to be very well correlated with those obtained on an ADAMS ™ A1c HA-8180V in Variant mode, making it suitable to use both systems running in parallel. The advantage of this "all in one" mode is that it offers both the high capability for HbA1c analysis of the HA-8180V Variant mode, and the added value of the screening for β thalassemia carriers; this model improves productivity and the whole laboratory process, allowing a lean rapid response.
It is not uncommon to detect an Hb variant in the course of routine monitoring of diabetes. 13 The additional benefit of the enhanced resolution to detect the presence of hemoglobinopathies is useful for two main reasons. First, the presence of Hb variants may interfere with HbA1c measurement, their influence having been well studied in various systems available on the market. 14 On the other hand, the presence of any abnormality is readily detected by the laboratory professional for further consideration of its implications by the physician, and is relevant for the interpretation of the HbA1c results and for genetic counselling. But in these patients with reduced erythrocyte life span, a non-hemoglobin based method should be used for assessing glycemic control, because the HbA1c level does not accurately reflect long-term glycemic control. 15, 16 In this study, a number of samples containing common variants were analyzed for HbA1c. The system adds flags and for HbS, HbC, and HbD makes a presumptive identification of the variant peak. A drawback of the system is that Hb Lepore co-elutes in the area of HbA 0 and HbA 2 , disrupting the chromatogram with a characteristic
HbA 0 peak. HbLepore may elute in both fractions, rendering a chromatogram in which no HbA2 peak can be recognized, and making it impossible to quantitate HbA1c and HbA 2 . HbE elutes on top of the HbA 2 peak. The system will add a flag for variant Hb: the operator will know that a variant is present because HbA 2 is rarely higher than 8%
in β-thalassemia trait. A drawback of the study is that it was not possible to verify the true effect of these variants on HbA1c quantitation (when the values are reported), due to the lack of a reference method to make the comparison.
In conclusion, the study has shown that the ADAMS ™ A1c HA 8180T system provides a rapid and reliable separation and determination of the relative percentage of different hemoglobin types, particularly HbA 2 . The results obtained are accurate and reproducible, with CVs lower than the strict quality requirements. This is a suitable system for the control of diabetic patients and the detection of Hb variants in laboratories with high workflow.
